Atlas Trials

EGFR Uncommon Mutations, Including G719X and S768I

1 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch EGFR Uncommon Mutations, Including G719X and S768I

RecordFirmDate
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations (NCT05364073)ArriVent BioPharma, Inc.2022-06-30

Track EGFR Uncommon Mutations, Including G719X and S768I automatically

Every clearance here is in the API, with alerts when new ones post.